Skip to content

Study · Case report or series · n = 1 · 2023

3 results

Tirzepatide-Induced Injection Site Reaction.

Mizumoto J

Cureus13 Sept 2023Cited by 9 (Europe PMC)

PMID37842452 (opens in a new tab)PMCIDPMC10575762 (opens in a new tab)DOI10.7759/cureus.45181 (opens in a new tab)PepBankPUB-37842452
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions. Injection site reactions are one of the potential adverse events associated with GLP-1 RA use. To the best of our knowledge, this is the first reported case of tirzepatide-induced injection site reaction.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A man developed an abdominal injection site rash after switching from dulaglutide to tirzepatide.

    In plain wordsA man developed a rash at the injection site after changing from dulaglutide to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseInjection site rash
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide.
  2. 02HumanCase report or seriesSafety outcome

    The man who developed a rash with tirzepatide had previously used dulaglutide without adverse reactions.

    In plain wordsThe man had no adverse reactions during earlier dulaglutide treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdverse reactions during prior treatment
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions.
    1 context sentence
    Summary · context
    A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide.

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 03HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome

    In a man with an injection site reaction, the rash diminished after tirzepatide withdrawal.

    In plain wordsA man's injection site rash decreased after tirzepatide stopped.

    Peptide
    Tirzepatide
    Outcome
    DecreaseRash after withdrawal
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    The rash diminished after stopping tirzepatide injection.
    1 context sentence
    Summary · context
    A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.